Alexander M. M. Eggermont, MD, PhD

Chief Scientific Officer, Board of Directors
University Medical Center Utrecht, Netherlands & Comprehensive Cancer Center Munich, Germany, United States

Presentation(s):

• 54: Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study

  Friday, March 24, 2023
  1:49 PM – 2:01 PM

  Disclosure information not submitted.